MT-2766, Adjuvanted COVID-19 Vaccine Candidate,
Confirms Positive Efficacy and Safety Results from Phase 3 Study Conducted in an Environment Dominated by the Variants

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President: Hiroaki Ueno), an operating company of Mitsubishi Chemical Holdings Corporation (Head Office: Tokyo; President: Jean-Marc Gilson), announced today results of clinical trials for MT-2766, a COVID 19 vaccine candidate as follows.

Mitsubishi Tanabe Pharma　Press Release
https://www.mt-pharma.co.jp/e/news/assets/pdf/e_MTPC211207.pdf